DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

VP Chavda, R Pandya… - Expert Review of …, 2021 - Taylor & Francis
ABSTRACT Introduction: Coronavirus outbreak 2019 (COVID-19) has affected all the
corners of the globe and created chaos to human life. In order to put some control on the …

Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity

H Zhang, J Vandesompele, K Braeckmans… - Chemical Society …, 2024 - pubs.rsc.org
Gene therapy is on its way to revolutionize the treatment of both inherited and acquired
diseases, by transferring nucleic acids to correct a disease-causing gene in the target cells …

B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response

E Andreano, I Paciello, G Pierleoni, G Piccini… - Nature …, 2023 - nature.com
The continuous evolution of SARS-CoV-2 generated highly mutated variants able to escape
natural and vaccine-induced primary immunity. The administration of a third mRNA vaccine …

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

A Alagheband Bahrami, A Azargoonjahromi… - Cellular & molecular …, 2022 - Springer
Designing and producing an effective vaccine is the best possible way to reduce the burden
and spread of a disease. During the coronavirus disease 2019 (COVID-19) pandemic, many …

Anatomy of Omicron BA. 1 and BA. 2 neutralizing antibodies in COVID-19 mRNA vaccinees

E Andreano, I Paciello, S Marchese, L Donnici… - Nature …, 2022 - nature.com
Abstract SARS-CoV-2 vaccines, administered to billions of people worldwide, mitigate the
effects of the COVID-19 pandemic, however little is known about the molecular basis of …

Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

V Fumagalli, P Di Lucia, M Ravà, D Marotta… - EMBO molecular …, 2023 - embopress.org
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

JL Torres, G Ozorowski, E Andreano… - Proceedings of the …, 2022 - National Acad Sciences
As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

[HTML][HTML] A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

L Aurisicchio, N Brambilla, ME Cazzaniga, P Bonfanti… - Molecular Therapy, 2023 - cell.com
The COVID-19 pandemic and the need for additional safe, effective, and affordable vaccines
gave new impetus into development of vaccine genetic platforms. Here we report the …

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)

R Baghban, A Ghasemian, S Mahmoodi - Archives of Microbiology, 2023 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has infected 673,010,496
patients and caused the death of 6,854,959 cases globally until today. Enormous efforts …

[HTML][HTML] DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic

A Villa, E Brunialti, J Dellavedova, C Meda… - Pharmacological …, 2022 - Elsevier
All the different coronavirus SARS-CoV-2 variants isolated so far share the same
mechanism of infection mediated by the interaction of their spike (S) glycoprotein with …